TY - JOUR
T1 - Transcatheter aortic valve implantation compared with surgical aortic valve replacement in patients with anaemia
AU - D’Errigo, Paola
AU - Biancari, Fausto
AU - Rosato, Stefano
AU - Tamburino, Corrado
AU - Ranucci, Marco
AU - Santoro, Gennaro
AU - Barbanti, Marco
AU - Ventura, Martina
AU - Fusco, Danilo
AU - Seccareccia, Fulvia
PY - 2017/7/25
Y1 - 2017/7/25
N2 - © 2017 Belgian Society of Cardiology Objectives: We compared the outcome of anaemic patients undergoing transcatheter (TAVI) and surgical aortic valve replacement (SAVR) for severe aortic valve stenosis. Methods: Anaemic patients (haemoglobin <13.0 g/dL in men and <12.0 g/dL in women) undergoing TAVI and SAVR from the OBSERVANT study were the subjects of this analysis. Results: Preoperative anaemia was an independent predictor of 3-year mortality after either TAVI (HR 1.37, 95% CI 1.12–1.68) and SAVR (HR 1.63, 95% CI 1.37–1.99). Propensity score matching resulted in 302 pairs with similar characteristics. Patients undergoing SAVR had similar 30-d mortality (3.6% versus 3.3%, p = .81) and stroke (1.3% versus 2.0%, p = .53) compared with TAVI. The rates of pacemaker implantation (18.6% versus 3.0%, p < .001), major vascular damage (5.7% versus 0.4%, p < .001) and mild-to-severe paravalvular regurgitation (47.4% versus 9.3%, p < .001) were higher after TAVI, whereas acute kidney injury (50.7% versus 27.9%, p < .001) and blood transfusion (70.0% versus 38.6%, p < .001) were more frequent after SAVR. At 3-year, survival was 74.0% after SAVR and 66.3% after TAVI, respectively (p = .065), and freedom from MACCE was 67.6% after SAVR and 58.7% after TAVI, respectively (p = .049). Conclusions: These results suggest that TAVI is not superior to SAVR in patients with anaemia.
AB - © 2017 Belgian Society of Cardiology Objectives: We compared the outcome of anaemic patients undergoing transcatheter (TAVI) and surgical aortic valve replacement (SAVR) for severe aortic valve stenosis. Methods: Anaemic patients (haemoglobin <13.0 g/dL in men and <12.0 g/dL in women) undergoing TAVI and SAVR from the OBSERVANT study were the subjects of this analysis. Results: Preoperative anaemia was an independent predictor of 3-year mortality after either TAVI (HR 1.37, 95% CI 1.12–1.68) and SAVR (HR 1.63, 95% CI 1.37–1.99). Propensity score matching resulted in 302 pairs with similar characteristics. Patients undergoing SAVR had similar 30-d mortality (3.6% versus 3.3%, p = .81) and stroke (1.3% versus 2.0%, p = .53) compared with TAVI. The rates of pacemaker implantation (18.6% versus 3.0%, p < .001), major vascular damage (5.7% versus 0.4%, p < .001) and mild-to-severe paravalvular regurgitation (47.4% versus 9.3%, p < .001) were higher after TAVI, whereas acute kidney injury (50.7% versus 27.9%, p < .001) and blood transfusion (70.0% versus 38.6%, p < .001) were more frequent after SAVR. At 3-year, survival was 74.0% after SAVR and 66.3% after TAVI, respectively (p = .065), and freedom from MACCE was 67.6% after SAVR and 58.7% after TAVI, respectively (p = .049). Conclusions: These results suggest that TAVI is not superior to SAVR in patients with anaemia.
KW - Anaemia
KW - anaemic
KW - aortic valve replacement
KW - aortic valve stenosis
KW - TAVI
KW - TAVR
UR - http://www.scopus.com/inward/record.url?scp=85031421555&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031421555&partnerID=8YFLogxK
U2 - 10.1080/00015385.2017.1327627
DO - 10.1080/00015385.2017.1327627
M3 - Article
AN - SCOPUS:85031421555
SP - 1
EP - 10
JO - Acta Cardiologica
JF - Acta Cardiologica
SN - 0001-5385
ER -